See every side of every news story
Published loading...Updated

Ozempic-like drug significantly reduces frequency of chronic migraines in pilot study

ITALY, JUL 2 – A 12-week trial showed liraglutide halved migraine days in 31 patients with obesity and chronic migraine unresponsive to other treatments, according to Italian researchers.

  • Italian researchers led by neurologist Simone Braca published this month a pilot study showing that liraglutide reduced migraine frequency in obese chronic migraine patients.
  • The small trial with 31 patients was motivated by the need for better treatments for high-frequency migraines unresponsive to current medications.
  • Participants received daily liraglutide injections for 12 weeks, after which average migraine days dropped from 19.8 to 10.7, nearly halving the monthly migraine burden.
  • One participant became completely free of migraines, while mild gastrointestinal side effects like nausea occurred but resolved, and researchers emphasized that the effect appeared independent of weight loss.
  • This proof-of-concept study suggests GLP-1 receptor agonists could offer a new treatment option for some chronic migraine sufferers and calls for larger trials to confirm these findings.
Insights by Ground AI
Does this summary seem wrong?

13 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 38% of the sources lean Left, 38% of the sources lean Right
38% Right

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Gizmodo broke the news in United States on Monday, June 30, 2025.
Sources are mostly out of (0)